Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The Phase IIb/III HVTN 702 trial will begin enrollment in southern African in the fall.
The final results of the HPTN 052 study of mixed-HIV-status, opposite-sex partners are in.
The accompanying editorial and press release to recent PARTNER study findings spark concerns from the Prevention Access Campaign.
People with a history of AIDS also face worse health outcomes following a stroke.
Meanwhile, their rates of other liver health problems are falling.
But some hard-hit risk groups and areas have been slow to adopt the HIV prevention method.
The trial will test giving the treatment every four weeks, which has controlled HIV better than the eight-week dosing schedule.
The open-label phase of the intercourse-based PrEP dosing study indicates the apparent risk-reduction power of the protocol.
The program also boosted the rates of HIV diagnosis and treatment.
U.S. PEPFAR funding favors nations with generalized epidemics.
Teenage gay and bi men's adherence to PrEP, good with monthly monitoring, declined with quarterly monitoring in a recent study.
Investigators have created a consortium hoping to yield HIV cures through stem cell transplants like the ones that cured the Berlin Patient.
Studies have shed new light onto why young women in South Africa have high rates of HIV infection and how to prevent the virus's spread.
Couples who received PrEP as a “bridge” to HIV treatment lowered their risk of transmission by 95 percent.
Women with HIV do better starting their first antiretroviral treatment regimen with Triumeq than with Norvir–boosted Reyataz plus Truvada.
HIV-positive breast-feeding mothers on antiretroviral treatment nearly eliminate their risk of transmitting the virus to their babies.